A powered exoskeleton, a wearable robotic frame that assists leg movement, changes recovery by adding intensive, repetitive walking practice to conventional therapy rather than replacing it. The practical shift is dose and support: patients can log more steps with adjustable assistance while therapists still direct strength, balance, and task training. For stroke recovery, the pattern is consistent across trials. Robotic gait training plus physiotherapy improves the chance of regaining independent walking, increases practice distance in the same session time, and produces small to moderate gains in walking ability and speed.
Table of Contents
- What happens differently in a robotic session?
- How much does walking improve?
- Who gains the most?
- What limits use right now?
What happens differently in a robotic session?
A conventional session depends heavily on therapist strength and patient fatigue. A therapist may manually support body weight, guide leg swing, and stop often for rest. Powered exoskeletons with adaptive bilateral assistance change that labor balance. The device supplies adjustable support to one or both legs.
Therapists can set high assistance early, then progressively reduce it as control returns. That lets them deliver intensive, repetitive, adjustable gait practice without replacing conventional strength, balance, and task training. In practice, this means longer continuous walking bouts and more symmetrical stepping. A randomized pilot trial in subacute stroke found the robotic group covered about twice the walking distance in the same time as conventional gait training. A trial of 30-minute EXOWALK training found comparable gains in walking function and gait symmetry to therapist-directed training.
How much does walking improve?
Cochrane's systematic review finds electromechanical and robotic gait training combined with physiotherapy probably helps stroke survivors regain independent walking, according to the Cochrane evidence review. Benefit is not uniform, and devices work as an add-on rather than a standalone cure. A 2023 meta-analysis of randomized trials of overground robotic exoskeletons reported a small post-treatment gain in walking ability, growing at follow-up, plus faster walking speed, as summarized in the Archives of Physical Medicine and Rehabilitation abstract.
A multicenter controlled trial of stationary robot-assisted gait training in subacute stroke reported larger improvements than conventional overground training in 10-meter walk performance, speed, endurance, balance, and daily activities. For automation readers, the key mechanism is repetition with control. Robots do not get tired, so step count and symmetry can stay high across a session. Therapist skill then goes into grading difficulty, correcting posture, and transferring gains to stairs, curbs, and home tasks.
Who gains the most?
Timing and initial ability matter. Cochrane's review points to the largest benefit in the first three months after stroke and in people initially unable to walk. Early intensive stepping appears to use a window when the nervous system is most responsive.
That does not mean later recovery is impossible. It means triage matters for scarce devices. Readers evaluating a program can ask: The goal is independent walking, not device walking. Programs should measure 10-meter speed, endurance, balance, and daily activities, then taper support.
- Is the patient in the subacute phase after stroke?
- Can the patient not yet walk independently?
- Can the center provide combined robot plus physiotherapy, not robot-only sessions?
- Is there a plan to reduce assistance and practice overground walking?
What limits use right now?
Regulatory clearance has widened, but access remains narrow. Ekso Bionics states its EksoNR/GT platform received FDA clearance for stroke and spinal cord injury rehabilitation in 2016, acquired brain injury in 2020, and multiple sclerosis in 2022, according to the FDA clearance announcement. Clearance is not the same as availability.
Most exoskeleton randomized trials are small and evidence certainty is very low. Cost and staffing restrict use, with about $77,000 reported for a ReWalk personal system and a need for trained centers, as reported in the AP/VA report. Patients should ask about out-of-pocket cost, session count, fall safeguards, skin and fit checks, and what conventional therapy continues alongside.
